2024 annual report is published
Report highlights progress in science, medicines and health in 2024
NewsHumanVeterinaryCorporate
EMA’s annual report 2024 published today gives insights into the Agency’s strategic priorities and contributions to public and animal health in the European Union (EU).
The digital report outlines the most important highlights regarding the evaluation and monitoring of human and veterinary medicines and a selection of key figures. The narrative is complemented by an interactive timeline of milestones in 2024, with advanced functionalities that allow readers to explore each topic in more depth by accessing additional documents, audio-visual materials and infographics.
In 2024, EMA recommended 114 medicines for marketing authorisation. Of these, 46 had a new active substance which had never been authorised in the EU before. Among these are a number of medicines that stand out due to their contribution to address public health needs or the innovation they represent.
On the veterinary side, EMA recommended 25 veterinary medicines for marketing authorisation – the highest number of recommendations in a year. Of these, two had a new active substance. 14 were vaccines, including seven that had been developed using a biotechnological process.
The report contains interviews with Bruno Sepodes, Chair of EMA’s human medicines committee (CHMP), Ulla Wändel Liminga, Chair of EMA’s safety committee (PRAC), and Gerrit Johan Schefferlie, Chair of EMA’s veterinary medicines committee (CVMP) who highlight some of the major achievements and activities of their committees in 2024 and outline their vision and priorities for next year.
Other important activities covered by the report include the Agency’s efforts to invest in better processes and evidence-based regulatory decisions, using initiatives such as Accelerating Clinical Trials in the EU (ACT EU) and the Data Analysis and Real World Interrogation Network (DARWIN EU), facilitating the uptake of advanced manufacturing methods and utilising artificial intelligence for the benefit of patients and public health; and EMA’s work to strengthen collaboration across the European medicines regulatory network and internationally.
As usual, the second chapter of the report is dedicated to core statistics and trends illustrating the Agency’s activities in the regulation of medicines. More detailed statistical information about EMA can be found in the Agency’s annual activity report.